Independent representation at the table — so you never overpay again.
A dedicated advisory division that helps practices evaluate, negotiate, and acquire capital equipment from any manufacturer. Vendor-neutral by design. Clients typically save $30K–$150K per device while acquiring the technology that actually fits their business model.
- ◆Practices evaluating one or more capital equipment purchases
- ◆Owners renegotiating leases or trade-ins
- ◆Groups building a multi-device technology roadmap
- ◆Every vendor swears theirs is the best; nobody is objective
- ◆Prices, warranties, and consumable costs are opaque
- ◆Trade-in and financing math is designed to confuse
- ◆Devices bought on emotion end up idle in month six
- — Independent technology evaluation across manufacturers
- — Vendor comparison matrix (price, ROI, consumables, warranty)
- — Lease vs. purchase vs. rev-share analysis
- — Contract review and redline recommendations
- — Live representation in vendor negotiations
- — Implementation and utilization plan post-purchase
- — 12-month multi-device technology roadmap
2–6 weeks per device · ongoing for roadmap clients
- — Average savings of $30,000–$150,000 per capital purchase
- — Contracts stripped of vendor-favorable clauses
- — Device utilization above 70% by month three
- — Long-term roadmap that ends impulse buying
No. Ever. That is the entire point of this service. Fees are paid by the practice only — that's what makes the advice worth taking.
Yes — that is a common engagement. We compare clinical performance, ROI per treatment, consumable cost, and vendor support head-to-head.
We review the contract, identify leverage, and often renegotiate terms or restructure the deal before the next payment cycle.
No commissions. No manufacturer allegiance. Every recommendation is paid for by you — and only by you.